Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) shows potential for significant upside, with a mean price target of $22.63 indicating a 45.8% increase from its current price of $15.52 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $3.25, suggesting variability in analyst predictions [2] - The lowest estimate of $18.00 indicates a 16% increase, while the highest estimate of $29.00 suggests an 86.9% surge [2] - Analysts' price targets can be misleading, as they may not accurately reflect future stock prices [3][7] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding ARQT's earnings prospects supports the view of potential upside [4][11] - Over the last 30 days, two earnings estimates have increased, leading to a 16.5% rise in the Zacks Consensus Estimate [12] - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting the extent of ARQT's gains, they can provide a directional guide for potential price movement [14]